Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sandoz Suffers Hefty 20% Price Cuts in FY2016 Revision, Teva 8.3%: Jiho Survey
March 8, 2016
- Kyowa Kirin Expects to Double Sales Force in US to Build Independent Marketing System; Anticipates Launch of Parkinson’s Drug in 2018
March 8, 2016
- Toyama Chemical Sues 3 Generic Firms over Ozex Patent
March 8, 2016
- Debiopharm Wins Elplat Patent Suit against Nippon Kayaku
March 8, 2016
- Z2 Price Cut Rule to Smash Mitsubishi Tanabe, Astellas, Pfizer: Jiho Tally
March 7, 2016
- Drug Price Cut to Net Out at 5.5% for Chugai, Gilead to Suffer 31.65% in Full: Jiho Tally
March 7, 2016
- Japan NDA Filed for Anti-HIV Drug Genvoya
March 7, 2016
- NHI Price Reduction Rates for Plavix Generics to Vary Largely between 17.1% and 59.5%: Jiho Tally
March 7, 2016
- Eisai Looks to Log Over 800 Billion Yen in FY2020, Lenvima as Key Growth Engine
March 4, 2016
- Teva Pharma Japan Voluntarily Recalling 7 Products
March 3, 2016
- Public Knowledge-Based Application Filed for Xeloda as Adjuvant Chemotherapy for Rectal Cancer: Chugai
March 3, 2016
- Pfizer Japan Chief Frets Possible Decline in Foreign Investments amid Anti-Innovation Drug Policies
March 3, 2016
- Pfizer’s Japan Sales Tick Up 2% in FY2015
March 3, 2016
- Takeda and Mizuho Medy Tie Up for Marketing of OTC Pregnancy Test Kit, Ovulation Predictor Kit
March 3, 2016
- Eisai Board OKs Hajime Shimizu as 1st President of EA Pharma
March 2, 2016
- Sakigake: Now and Future (4) - MSD’s Anti-PD-1 Antibody Gets Sakigake Designation for Gastric Cancer, While Opdivo also Under Development for Same Indication
March 2, 2016
- Drug Wholesalers’ Inventory Margins Likely to Diminish for FY2016 Price Revision
March 1, 2016
- MSD Seeks Lung Cancer Indication for Pembrolizumab in Japan
March 1, 2016
- Shionogi Links Arms with Roche on Sakigake-Designated Anti-Flu Drug
March 1, 2016
- New Presidents Announced for Alfresa, Suzuken, Fuji Pharma
February 29, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…